Spectrum Pharmaceuticals to Present at the 2009 BIOCOM Investor Conference
More News related to SPPI
- Spectrum Pharma (SPPI) Files $250M Mixed Shelf
- Spectrum Pharma (SPPI) and Handok Pharma Announce Plans for Apaziquone Development in South Korea
- Spectrum Pharmaceuticals and Handok Pharmaceuticals Announce Collaboration Agreement for Apaziquone in South Korea
- Spectrum Pharmaceuticals Added to NASDAQ Biotechnology Index
- Semi-Annual Changes to the NASDAQ Biotechnology Index
IRVINE, Calif.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals, Inc. (NasdaqGM: SPPI), a commercial-stage biotechnology company with a focus in oncology, announced today that an overview of the Company's business strategy will be presented at the 2009 BIOCOM Investor Conference on Tuesday, October 27, 2009 at 9:30am Pacific Time. The conference is being held at the Hyatt Regency La Jolla, in La Jolla, California.
The live webcast of Spectrum's presentation will be available at http://www.sppirx.com.
About Spectrum Pharmaceuticals
We are a commercial-stage biotechnology company with a focus primarily in oncology. Our strategy is comprised of acquiring and developing a broad and diverse pipeline of late-stage clinical and commercial products; establishing a commercial organization for our approved drugs; continuing to build a team with people who have demonstrated skills, passion, commitment and have a track record of success in our areas of focus; and, leveraging the expertise of partners around the world to assist us in the execution of our strategy. For more information, please visit our website at www.sppirx.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements include but are not limited to statements that relate to our business and its future, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, establishing a commercial organization for our approved drugs, continuing to build our team, leveraging the expertise of partners around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. (TM), TURNING INSIGHTS INTO HOPE(TM) and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.
(C) 2009 Spectrum Pharmaceuticals, Inc. All Rights Reserved.
Source: Spectrum Pharmaceuticals, Inc.
Related Categories
Press ReleasesStocks Mentioned
-0.24Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
